These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33496861)

  • 1. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
    J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    Morales FS; Koralnik IJ; Gautam S; Samaan S; Sloane JA
    J Neurol; 2020 Jan; 267(1):125-131. PubMed ID: 31583427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
    Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
    Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
    Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
    Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
    Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
    Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis.
    Ravn J; Jensen HB; Kant M; Andersen PB; Góra MK; Sejbaek T
    Mult Scler Relat Disord; 2022 Nov; 67():104081. PubMed ID: 35944466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worsening of lymphopenia in patients with multiple sclerosis when switched from dimethyl fumarate to diroximel fumarate.
    Dempsey JP; Wu L; Balshi A; Jun C; Baber U; Sloane JA
    Mult Scler Relat Disord; 2024 Sep; 89():105737. PubMed ID: 39029343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
    Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between lymphopenia and disease activity in persons with multiple sclerosis treated with dimethyl fumarate.
    Chu L; Balusha A; Casserly C; Berger W; Morrow SA
    Mult Scler Relat Disord; 2022 Jan; 57():103384. PubMed ID: 35158477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Caldito NG; O'Leary S; Stuve O
    Mult Scler; 2021 Jul; 27(8):1306-1308. PubMed ID: 33620273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bariatric surgery and dimethyl fumarate-induced lymphopenia in patients with multiple sclerosis.
    Andreozzi V; Capuano R; Scannapieco S; Barra F; d'Arco B; Giordano C; Caterino M; De Marca U; Di Filippo F; Di Gregorio M; Barone P
    Neurol Sci; 2024 Jun; 45(6):2807-2810. PubMed ID: 38150132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
    Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
    Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes.
    Dinoto A; Sartori A; Cheli M; Pasquin F; Baldini S; Bratina A; Bosco A; Manganotti P
    Mult Scler Relat Disord; 2022 Jan; 57():103357. PubMed ID: 35158466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
    Tsantes E; Curti E; Ferraro D; Lugaresi A; Baldi E; Montepietra S; Immovilli P; Simone AM; Mancinelli L; Strumia S; Vitetta F; Foschi M; Ferri C; Ferrarini C; Sola P; Granella F
    Eur J Neurol; 2021 Jan; 28(1):269-277. PubMed ID: 32931130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
    Sabin J; Urtiaga S; Pilo B; Thuissard I; Galan V; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Martínez-Ginés ML; Lozano A; Borrega L; Ayuso L; Castro A; Sanchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodriguez-García E; Moreno I; García-Merino JA; Aladro Y;
    J Neurol; 2020 Aug; 267(8):2362-2371. PubMed ID: 32350647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
    Smoot K; Spinelli KJ; Stuchiner T; Lucas L; Chen C; Grote L; Baraban E; Kresa-Reahl K; Cohan S
    Mult Scler; 2018 Jun; 24(7):942-950. PubMed ID: 28537110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with dimethyl fumarate-induced lymphopenia.
    Sainz de la Maza S; Medina S; Villarrubia N; Costa-Frossard L; Monreal E; Tejeda-Velarde A; Rodríguez-Martín E; Roldán E; Álvarez-Cermeño JC; Villar LM
    J Neurol Sci; 2019 Mar; 398():4-8. PubMed ID: 30658226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of persistent lymphopenia in people with multiple sclerosis on dimethyl fumarate.
    Wood CH; Robertson NP; Htet ZM; Tallantyre EC
    Mult Scler Relat Disord; 2022 Feb; 58():103492. PubMed ID: 35066268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia.
    Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Tremlett H
    BMJ Open; 2017 Jun; 7(5):e016276. PubMed ID: 28576902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.